Ascendis FY results a bitter pill to swallow

PUBLISHED: Thu, 31 Oct 2019 11:21:21 GMT


Pharmaceutical group Ascendis Health has released its twice delayed annual results with a reported normalised loss after tax of R459 million. The company is also looking to sell off non-core assets after its share price has come under severe pressure this year which they have attributed to impairment costs of R4.2 billion. Ascendis Health CEO, Mark Sardi joins CNBC Africa for more.

Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent. Sign up here.